跳至主要内容
临床试验/NCT03293511
NCT03293511Unknown不适用

Oxytocin Modulates Eye Gaze Behavior During Social Processing and Associations With Trait Autism

University of Electronic Science and Technology of China2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2017年6月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
40
试验地点
2
主要终点
Global eye gaze characteristic: differences between oxytocin and placebo treatment

研究概览

简要总结

The main aim of the study is to examine whether the effects of intranasal oxytocin on eye-gaze behavior towards social stimuli are modulated via individual differences in trait autism

详细描述

In this double-blind, within subject, placebo controlled design a total of n = 40 healthy male subjects will receive either 24 IU of oxytocin or placebo (interval between administration > two weeks). 45 minutes after treatment subjects will undergo a total of 7 eye-tracking paradigms examining eye-gaze behavior during social processing: (1) dynamic social-nonsocial visual preference task during which movies of dynamic geometric images (DGI) and dynamic social images (DSI) will be presented; (2) non-biological versus biological motion task; (3) social attention and motivation of sharing enjoyment; (4) preference for emotional faces versus schematic faces (emoticons); (5) shared social attention - shared gaze direction with an actor shifting his attention to different objects; (6) preferred visual scanning of face regions in emotional faces; and, (7) eye gaze in response to empathy eliciting visual stimuli. Autistic and associated traits will be assessed using the Autism Spectrum Quotient (ASQ), Social Responsibilities Scale (SRS) and the Interpersonal Reactivity Index (IRI). Within-subject differences in the effects of oxytocin on social eye gazing behaviour will be related to individual differences in autistic traits.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 30 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy subjects without any past or present psychiatric or neurological disorders

排除标准

  • History of brain injury
  • Visual impairments
  • Use of medication
  • Contraindications for oxytocin administration

研究组 & 干预措施

Order of administration: oxytocin - placebo

Experimental

Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray

干预措施: intranasal oxytocin (Drug)

Order of administration: oxytocin - placebo

Experimental

Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray

干预措施: intranasal placebo (Drug)

Order of administration: placebo - oxytocin

Experimental

Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).

干预措施: intranasal oxytocin (Drug)

Order of administration: placebo - oxytocin

Experimental

Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).

干预措施: intranasal placebo (Drug)

结局指标

主要结局

Global eye gaze characteristic: differences between oxytocin and placebo treatment

时间窗: 45-90 minutes after treatment administration

Global eye-gaze patterns will be compared between the administration of oxytocin and placebo

Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment

时间窗: 45-90 minutes after treatment administration

Localized feature-specific eye gaze patterns will be compared between oxytocin and placebo treatment

次要结局

  • Global eye gaze characteristic - associations with autism traits(45-90 minutes after treatment administration)
  • Feature-specific eye gaze characteristics - associations with trait autism(45-90 minutes after treatment administration)

研究者

发起方
University of Electronic Science and Technology of China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Keith Kendrick

Professor

University of Electronic Science and Technology of China

研究点 (2)

Loading locations...

相似试验